Paul Mampilly Reviews Amazon’s Forays IntoHealthcare
Amazon traces its roots to an innovative digital bookstore. Today, it is in almost every sector of the online economy. The online giant is looking to get into the healthcare market. This move has financial experts such as Paul Mampilly worried. He is a prominent Wall Street veteran with extensive experience managing hedge funds and investment banking. When it does make the foray into healthcare, Amazon will grab dividend-paying stocks.
The Auto Industry Is About to Completely Change.#AutonomousVehicles #AutonomousCars #Waymo #driverlesscars #technology #ridesharing #banyanhill #Automotive #Automotive $F $GM $FCAUhttps://t.co/zzn3rNnpRd
— Paul Mampilly (@Paul_M_Guru) November 9, 2017
Thousands of his readers hold the same stocks. Paul Mampilly describes a phenomenon where stock prices plummet after being targeted by Amazon. The online conglomerate has its eyes set on the prescription drugs segment. There is a complex pricing mechanism, which factors in production costs, research and development, distribution and marketing channels used to sell the drugs. It involves pharmaceuticals, pharmacies, insurers, benefit managers, and distributors.
Multiple studies into the rising healthcare budget indicate that the highest percentage goes to prescription drugs. The current supply chain system is thought to be rigged in favor of brokers and insurance companies. Patients and taxpayers bear the brunt of the process. Amazon is reported to be looking to take to the big pharmacy chain model.
This will force the sector to pay more attention to pricing strategies and transparency; two elements that brokers and distributors exploit to obtain huge profits. The first revolution will hit when the agents start feeling the squeeze on their revenues. Big name pharmacy chains such as CVS and Express Scripts are already experiencing a drop in stock prices. These signs indicate the markets are getting ready for the online giant’s entry into the market.
Besides Amazon, the only other winners in this equation are the patients who will get quality medications at a fraction of the cost. Paul Mampilly suggests you hold off boosting your healthcare stocks as they are expected to head south. He built a lucrative career on Wall Street in various executive roles. He has worked for big names such as ING and Deutsche Bank.
At the height of his career, Paul Mampilly changed tactic to focus on private investments and financial advisory. He runs Profits Unlimited, a publication of Banyan Hill. Additionally, he oversees two premier trading services including Extreme Fortunes, a heady guide into wildly lucrative options, and True Momentum, the perfect guide to medium-risk opportunities with high-yields.
Close to a hundred thousand followers depend on his advice to grow and protect their portfolios. His strategies are on point helping average Americans make sense of the financial markets and benefit from Wall Street.
About Paul Mampilly: banyanhill.com/expert/paul-mampilly/